Skinhealth Systems Inc. · NASDAQ:SKIN
Skinhealth Systems — Q1 2026 Earnings Presentation
16 slides from Skinhealth Systems's earnings presentation, May 7, 2026
Slide 1: Q1 2026 Financial Results
Q1 2026 Financial Results May 7, 2026
Slide 2: Disclaimer
Disclaimer This Presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, expectations of future ope
Slide 3: Strategic Objective
Strategic Objective Establish SkinHealth Systems as a leader in medical aesthetics, delivering an ecosystem of solutions that uniquely combines device, consumables, clinical credibility, and brand power to achieve superior skin health for consumers and positive economic outcomes for providers. 3
Slide 4: The Global Medical Aesthetics Market
The Global Medical Aesthetics Market Growing & Increasingly Favorable to SkinHealth Systems Large and addressable global Clinical validation helping to drive market driven by innovation provider and consumer adoption Combination treatments Skin health is becoming a increasing in popularity, driving
Slide 5: Opportunity to leverage our assets to drive profitable growth
Opportunity to leverage UNIQUE our assets to drive ECONOMIC MODEL profitable growth Profitable unit economics on equipment sales and long-tailed, durable recurring cash flow from consumables sales COMPELLING BRAND EQUITY IN LOYAL PROVIDERS HYDRAFACIAL Adored by providers for attractive economics #2
Slide 6: Roadmap to Accelerate Growth
Roadmap to Accelerate Growth PHASE 1 PHASE 2 PHASE 3 Stabilize & Invest Launch New Products Accelerate in Innovation 6
Slide 7: Phase 1: Stabilize & Invest in Innovation - 2026 Critical Success Factors
Phase 1: Stabilize & Invest in Innovation - 2026 Critical Success Factors to help accelerate growth SALESFORCE EXECUTION MARKETING EXCELLENCE PRODUCT INNOVATION • Sharpening our clinical and economic • Driving new consumer demand and • Investing in science-backed value proposition refining brand pos
Slide 8: Corporate Rebrand
Corporate Rebrand "This is not simply a change in name. It represents a fundamental evolution in how we operate, and how we intend to compete. Our focus is on building a durable, scalable ecosystem of skin health technologies and solutions that delivers consistent, provider- led outcomes and creates
Slide 9: Q1 2026 Financial Highlights and Guidance
Q1 2026 Financial Highlights and Guidance 9
Slide 10: First Quarter 2026 Financial Highlights
First Quarter 2026 Financial Highlights Net Delivery Systems Net Consumables Net Income Adjusted 1 Sales Sales Net Sales (Loss) EBITDA $64.9m $18.5m $46.4m $(6.6)m $8.5m -6.7% YoY -8.3% YoY -6.1% YoY +$3.5m YoY +$1.2m YoY Primarily impacted by lower Decrease in delivery systems Consumables net sales
Slide 11: Revised 2026 Financial Guidance
Revised 2026 Financial Guidance 2Q 2026 FY 2026 $72 – $77m $280 – $295m 2Q 2026E net sales FY 2026E net sales $11 – $13m $35 – $45m 2Q 2026E adjusted EBITDA1 FY 2026E adjusted EBITDA1 11 1. Adjusted EBITDA is a non-GAAP measure; please refer to the disclaimer for a discussion of the definition of th
Slide 12: Appendix: Non-GAAP Financial Reconciliations
Appendix: Non-GAAP Financial Reconciliations 12
Slide 13: Reconciliation of gross profit to adjusted gross profit
Reconciliation of gross profit to adjusted gross profit Three Months Ended March 31 Unaudited ($ in millions) 1 2026 2025 Net sales $ 64.9 $ 69.6 Gross profit $ 44.4 $ 48.6 Gross margin 68.5% 69.8% Adjusted to exclude the following: Depreciation expense 0.2 0.2 Amortization expense 2.1 1.1 Share-bas
Slide 14: Reconciliation of operating expenses to adjusted operating expenses
Reconciliation of operating expenses to adjusted operating expenses Three Months Ended March 31 Unaudited ($ in millions) 1 2026 2025 Total operating expenses $ 46.2 $ 60.6 Adjusted to exclude the following: Depreciation expense 0.4 1.6 Amortization expense 2.7 3.2 Share-based compensation expense a
Slide 15: Reconciliation of net loss to adjusted EBITDA
Reconciliation of net loss to adjusted EBITDA Three Months Ended March 31 Unaudited ($ in millions) 1 2026 2025 Net sales $ 64.9 $ 69.6 Net loss $ (6.6) $ (10.1) Net loss margin (10.2%) (14.5%) Adjusted to exclude the following: (Benefit) expense for income taxes (0.2) 0.9 Depreciation expense 0.6 1
Slide 16: SYSTEMS
SYSTEMS